Model Name
Pulmonary, Lipopolysaccharide-Induced Neutrophilia, Rat

Item Number
572110

Introduction
In vivo pharmacology assays may serve to extend in vitro results or detect potentially important primary and/or secondary pharmacodynamic activities. Semi-quantitative or quantitative data can be generated on request.

Procedure Summary
N/A

Suggested Testing
- n=5/group
- Safety non-GLP: 3 doses + vehicle control groups, n=4–10/group
- Agonist and/or antagonist effects assessed at initial doses of 30–100 mg/kg as aqueous solutions or finely homogenized suspensions in 2% Tween 80/distilled water and administered p.o. or i.p. to mice, rats, guinea pigs (10 mL/kg); i.v., i.p., or s.c. in
- Automatic minimum effective dose (MED) determined when activity >50% detected in accordance with stated criteria
- 3 dose levels in safety non-GLP procedures

Turnaround Time(s)
- For Acute Assays: 4 weeks from sample receipt
- For Subacute Assays: 6 weeks to 3 months

Literature

Related Assay(s)  (Item # - Assay Name - Species)
576700 - Septic Shock, Lipopolysaccharide - Mouse
576750 - Septic Shock, Lipopolysaccharide - Rat

Modified Protocols
We will readily accommodate client-specified alterations.

Laboratory
These assays are performed at our AAALAC accredited laboratory in Taipei.

Animal Welfare
All aspects of this work is performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.

Reference Compound(s)
Dexamethasone 21-acetate

Last modified September 15, 2017